|Pimasertib (AS-703026)MEK1/2 inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Description||Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 values of 5 nM-2 μM in human multiple myeloma (MM) cell lines.|
|IC50||5 nM-2 μM|
|Cas No.||1236699-92-5||SDF||Download SDF|
|Solubility||Soluble in DMSO > 10 mM||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
IC50: ranging from 0.005 to 2 μM for the growth of MM cell lines
The MEK/ERK pathway transmits mitogenic signals to the nucleus and thus regulates the expression of genes that are critical for survival, proliferation, and differentiation. This pathway is often upregulated in cancer as result of oncogenic mutations. MEK is a crucial kinase in this pathway and has been targeted for the therapeutic agents development that block the MEK/ERK signaling cascade. AS 703026 is a novel small molecule MEK inhibitor.
In vitro: AS 703026 binds to the distinctive MEK allosteric site and therefore exhibits exquisite kinase selectivity. The AS 703026 binding to MEK is independent of ATP, and results in enzyme inhibition by prevention of activation. This inhibitor shows strong antiproliferative effect on tumor cell lines bearing oncogenic mutations or amplifications along the MEK/ERK pathway .
In vivo: In relevant mouse xenograft models, AS 703026 inhibits tumor growth after oral administration. The effect on tumor growth is dose-dependant and correlates with target modulation in both tumors and blood .
Clinical trial: 16 patients were enrolled in the trial. 10 and 6 patients were treated daily with 45 and 60 mg of AS 703026 plus FOLFIRI, respectively. The MTD was considered to be 45 mg/day. Of the 15 patients in the efficacy analysis group, 2 patients had partial response, 9 patients had stable disease, 3 patients had progressive disease as their best overall response and 1 patient could not be evaluated.
 Goutopoulos A, Askew BC, Bankston D, Clark A, Dhanabal M, Dong R, Fischer D, Healey B, Jiang X, Josephson K, Lin J, Ma J, Noonan T, Qiu D, Rocha C, Romanelli A, Shutes A, Spooner E, Tian H, H Y. AS703026: a novel allosteric MEK inhibitor. AACR Annual meeting. 2009 Abstract#4776.
 Macarulla T, Cervantes A, Tabernero J et al. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Br J Cancer. 2015 Jun 9;112(12):1874-81.